ea2

Bridging the gap between scientific discovery and investment-ready innovation for rare disease breakthroughs.

ERDERA Technology Accelerator

The ERDERA Technology Accelerator advances the enabling technologies that make rare-disease therapies possible. We bring public and private partners together to mature, validate, and streamline advanced therapy platforms so promising discoveries can move faster, safer, and more efficiently toward the clinic.

By strengthening shared technological toolboxes for the rare disease community, we help reduce development risk and accelerate translation across multiple indications.

You are a technology developer…

…working on enabling technologies for rare-disease therapies within academia, a research infrastructure, an SME, or industry.

…developing platforms such as viral or non-viral delivery systems, gene-editing tools, therapeutic RNAs, or analytical and manufacturing solutions.

…looking to improve robustness, scalability, comparability, or clinical relevance of your technology through collaboration and real-world feedback.

If this sounds like you, the Technology Accelerator can help.

 

The Technology Accelerator supports partners by:

Advancing enabling ATMP technologies, including:

Adeno-associated Virus (AAVs)

Messenger RNA (mRNA)

Lipid Nanoparticles, Extracellular Vesicles, Biohybrids

Gene Editing Tools

Addressing key technical bottlenecks across:

Delivery efficiency and tissue targeting

Manufacturing and scale-up

Analytical characterisation and quality control

Evaluation of therapy response, safety, and immunogenicity

Facilitating pre-competitive collaboration between public and private stakeholders to strengthen shared technology platforms.

Aligning technology development with translational and clinical needs in rare diseases.

Advancing enabling ATMP technologies, including:

  • Adeno-associated Virus (AAVs)
  • Messenger RNA (mRNA)
  • Lipid Nanoparticles, Extracellular Vesicles, Biohybrids
  • Gene Editing Tools

Addressing key technical bottlenecks across:

  • Delivery efficiency and tissue targeting
  • Manufacturing and scale-up
  • Analytical characterisation and quality control
  • Evaluation of therapy response, safety, and immunogenicity

Networking

Facilitating pre-competitive collaboration between public and private stakeholders to strengthen shared technology platforms.

Alignment

Aligning technology development with translational and clinical needs in rare diseases.

Robust, well-validated enabling technologies are essential for translating rare-disease discoveries into viable therapies. By strengthening these foundations, the Technology Accelerator supports not just individual projects but the entire rare-disease innovation ecosystem.

Understand the concept of ATMPs with this Knowledge Pill

The role of National Mirror Groups (NMGs)

Cover of the 16-country rare disease policy assessment, October 2026.

Reckoning With the Rare Disease Landscape. A 16 Country Policy Landscape Assessment across the Life Course.

The assessment compares diagnosis, treatment access and national governance across 16 countries, examining gaps in rare disease support throughout the life course.
ERDERA JTC 2027 pre-announcement cover

ERDERA 2027 Joint Transnational Call – Pre-announcement

The document outlines the Call's 2027 proposed research scope, eligibility criteria, consortium requirements and preliminary application timetable for multinational collaborations on recently identified rare diseases.
A European Blueprint for Rare Diseases

A European Blueprint for Rare Diseases: Towards an EU Action Plan for Rare Diseases

The European Blueprint sets out how Europe can build on initiatives such as ERDERA to turn existing expertise into a more coordinated future for rare diseases.
erdera policy brief data OCT2026

ERDERA Policy Brief: Making all data count for rare disease research and health outcomes – from policy recommendations to implementation

Making all data count for rare disease research and health outcomes – from policy recommendations to implementation

Latest relevant publications

generic scientific publication image

Leveraging precompetitive collaborations for rare diseases

The editorial examines how shared frameworks, data standards, infrastructure and governance can help stakeholders address common barriers in rare disease research and medicine development.
ERDERA clinical trial call

ERDERA Clinical Trial Call – Model Award Agreement

Model award agreement document setting out the structure, articles and contractual provisions applicable to funded activities.
ERDERA clinical trial call

ERDERA Clinical Trial Call – Annex IV. Guidelines for Canadian Applicants

This annex explains the specific eligibility, sponsorship, funding and application requirements for Canadian applicants in the ERDERA Clinical Trial Call.
ERDERA clinical trial call

ERDERA Clinical Trial Call – Call Text

Call text draft setting out rules, eligibility and staged application process for the ERDERA Clinical Trial Call 2026.

ERDERA Search